All In Biotech

Drug Trial Radar · NCT01961921

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02

Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Oct 2013

Primary completion

Jul 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Oct 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

Conditions

  • TTR-mediated Amyloidosis

Interventions

  • ALN-TTR02 (patisiran) administered by intravenous (IV) infusionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug DiscontinuationTime frame: From Baseline up to 56 days post last dose

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    Le Kremlin-Bicêtre, France

  • Clinical Trial Site

    Marseille, France

  • Clinical Trial Site

    Münster, Germany

  • Clinical Trial Site

    Lisbon, Portugal

  • Clinical Trial Site

    Porto, Portugal

  • Clinical Trial Site

    Palma de Mallorca, Spain

  • Clinical Trial Site

    Umeå, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.